IP Library Granted Patent US 8,744,546
Granted Patent B2
US 8,744,546 · App. 11/413,238 · Granted Jun 3, 2014

Cellulosic-based resistance domain for an analyte sensor

Inventors: James R. Petisce (San Diego, CA); Kum Ming Woo (San Diego, CA); Victor Ha (Saint Louis, MO); Melissa Nicholas (San Diego, CA)
Assignee: DexCom, Inc.
A61B5/14532A61B5/14865A61B5/1473A61B5/14503
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,744,546
App. No.
11/413,238
Granted
Jun 3, 2014
Kind
B2
Abstract

The present invention relates generally to devices for measuring an analyte in a host. More particularly, the present invention relates to devices for measurement of glucose in a host that incorporate a cellulosic-based resistance domain.

Claims (23)

1. An implantable glucose sensor for measuring a concentration of glucose in a host, the sensor comprising an electroactive surface and a membrane system disposed thereon, wherein the membrane system comprises a macromolecular resistance domain configured to control a flux of glucose therethrough, wherein the membrane is configured to use oxygen from a biological fluid surrounding the membrane to catalyze a reaction of glucose and oxygen, and wherein the macromolecular resistance domain comprises at least one hydrophilic moiety and at least one hydrophobic moiety; wherein the sensor is configured for implantation into a host, and wherein the sensor in vitro is capable of obtaining substantial linearity at glucose concentrations of from about 40 mg/dL to about 400 mg/dL at an oxygen concentration of about 0.25 mg/L.

2. The sensor of claim 1 , wherein the hydrophobic moiety is selected from the group consisting of acetyl, butyryl, propionyl, methoxy, ethoxy, and propoxy.

3. The sensor of claim 2 , wherein the hydrophobic moiety is acetyl.

4. The sensor of claim 3 , wherein the macromolecular resistance domain comprises less than about 35 wt. % acetyl.

5. The sensor of claim 1 , wherein the hydrophilic moiety is selected from the group consisting of hydroxyl, carboxymethyl, and carboxyethyl.

6. The sensor of claim 5 , wherein the hydrophilic moiety is hydroxyl.

7. The sensor of claim 6 , wherein the macromolecular resistance domain comprises at least about 7 wt. % hydroxyl.

8. The sensor of claim 1 , wherein the sensor is a needle sensor configured for transcutaneous insertion into the host.

9. The sensor of claim 1 , wherein the sensor is configured for wholly implanting into the host.

10. The sensor of claim 1 , wherein the sensor is configured for implantation into a host tissue, and wherein the resistance domain is configured to interface with the host tissue.

11. The sensor of claim 1 , wherein the resistance domain is a bioprotective barrier configured to protect the sensor from cellular invasion.

12. The sensor of claim 1 , wherein the membrane system is an ionizing radiation-treated membrane system.

13. An implantable glucose sensor for measuring glucose in a host, the sensor comprising an electroactive surface and a membrane system disposed thereon, wherein the membrane is configured to use oxygen from a biological fluid surrounding the membrane to catalyze a reaction of glucose and oxygen, wherein the membrane system comprises a resistance domain configured to control a flux of glucose therethrough, and wherein the resistance domain incorporates hydrophilic substituents and hydrophobic substituents to form a macromolecular structure; wherein the sensor is configured for implantation into a host, and wherein the sensor in vitro is capable of obtaining substantial linearity at glucose concentrations of from about 40 mg/dL to about 400 mg/dL at an oxygen concentration of about 0.25 mg/L.

14. The sensor of claim 13 , wherein the hydrophobic substituent is selected from the group consisting of acetyl, butyryl, propionyl, methoxy, ethoxy, and propoxy.

15. The sensor of claim 13 , wherein the hydrophobic substituent is acetyl.

16. The sensor of claim 15 , wherein the macromolecular resistance domain comprises less than about 35 wt. % acetyl.

17. The sensor of claim 13 , wherein the hydrophilic substituent is selected from the group consisting of hydroxyl, carboxymethyl, and carboxyethyl.

18. The sensor of claim 13 , wherein the hydrophilic moiety is hydroxyl.

19. The sensor of claim 18 , wherein the macromolecular resistance domain comprises at least about 7 wt. % hydroxyl.

20. The sensor of claim 13 , wherein the sensor is a needle sensor configured for transcutaneous insertion into the host.

21. The sensor of claim 13 , wherein the sensor is configured for implantation into a host tissue, and wherein the resistance domain is configured to interface with the host tissue.

22. The sensor of claim 13 , wherein the resistance domain is a bioprotective barrier configured to protect the sensor from cellular invasion.

23. The sensor of claim 13 , wherein the membrane system is an ionizing radiation-treated membrane system.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2006
From: PETISCE, JAMES R.; WOO, KUM MING; HA, VICTOR; NICHOLAS, MELISSA
To: DEXCOM, INC.
Reel/Frame 017822/0183 →
Continuity (2)
Provisional Application 60678373 · May 5, 2005
Related Publication 20060253012A1 · Nov 9, 2006